Amplia Therapeutics Sets EGM for Shareholder Approvals
FDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER
Amplia Therapeutics Director Increases Stake
Pengana Capital Reduces Stake in Amplia Therapeutics
Amplia Therapeutics Secures Key Narmafotinib Patent
No Data
No Data